Scenario | Item | Strategy 1 | Strategy 2 | Strategy 3 | Strategy 4 | Strategy 5 | Strategy 6 | Strategy 7 | Strategy 8 | Strategy 9 | Strategy 10 |
---|---|---|---|---|---|---|---|---|---|---|---|
Discount rate (costs and benefits) 3.5% | Cost, ¥ ($)a | 49,164 (7117) | 74,539 (10,790) | 52,418 (7588) | 77,860 (11,271) | 56,539 (8185) | 82,183 (11,897) | 51,865 (7508) | 77,920 (11,280) | 64,782 (9378) | 90,586 (13,113) |
QALY | 13.289 | 13.317 | 13.300 | 13.330 | 13.339 | 13.368 | 13.401 | 13.429 | 13.368 | 13.397 | |
Rankb | 5 | 9 | 6 | 10 | 2 | 7 | 1 | 4 | 3 | 8 | |
Simulation time 30 years | Cost, ¥ ($)a | 49,520 (7169) | 73,411 (10,627) | 52,981 (7669) | 76,934 (11,137) | 57,369 (8305) | 81,512 (11,800) | 52,475 (7596) | 77,009 (11,148) | 66,122 (9572) | 90,417 (13,089) |
QALY | 13.615 | 13.639 | 13.627 | 13.652 | 13.666 | 13.692 | 13.730 | 13.755 | 13.696 | 13.721 | |
Rankb | 5 | 9 | 6 | 10 | 2 | 7 | 1 | 3 | 4 | 8 | |
HbA1c thresholds of 7% and 8% for two therapy escalations | Cost, ¥ ($)a | 65,349 (9460) | 152,597 (22,090) | 68,402 (9902) | 155,817 (22,556) | 72,036 (10,428) | 160,022 (23,165) | 66,064 (9563) | 155,819 (22,556) | 79,592 (11,522) | 168,147 (24,341) |
QALY | 14.110 | 14.202 | 14.120 | 14.214 | 14.168 | 14.263 | 14.307 | 14.399 | 14.219 | 14.313 | |
Rankb | 4 | 9 | 5 | 10 | 3 | 8 | 1 | 6 | 2 | 7 | |
Use UKPDS 82 risk equations to run model | Cost, ¥ ($)a | 57,572 (8334) | 91,305 (13,217) | 61,250 (8867) | 95,044 (13,759) | 65,866 (9535) | 99,854 (14,455) | 58,536 (8474) | 85,614 (12,393) | 74,606 (10,800) | 108,863 (15,759) |
QALY | 14.529 | 14.567 | 14.532 | 14.570 | 14.557 | 14.595 | 14.587 | 14.397 | 14.606 | 14.643 | |
Rankb | 2 | 6 | 5 | 9 | 4 | 8 | 1 | 10 | 3 | 7 | |
Utility impact is + 0.017 and − 0.047 for per unit decrease and increase in BMI [365] | Cost, ¥ ($)a | 52,923 (7661) | 81,569 (11,808) | 56,374 (8161) | 85,095 (12,318) | 60,741 (8793) | 89,690 (12,984) | 55,729 (8067) | 85,142 (12,325) | 69,467 (10,056) | 98,597 (14,273) |
QALY | 14.446 | 14.510 | 14.476 | 14.541 | 14.566 | 14.632 | 14.830 | 14.894 | 14.651 | 14.717 | |
Rankb | 8 | 10 | 6 | 9 | 4 | 7 | 1 | 2 | 3 | 5 | |
Probabilistic sensitivity analysis | Cost, ¥ ($)a | 52,563 (7609) | 82,077 (11,881) | 56,194 (8135) | 86,234 (12,483) | 60,440 (8749) | 90,647 (13,122) | 55,150 (7983) | 85,090 (12,318) | 69,411 (10,048) | 99,640 (14,424) |
QALY | 13.897 | 13.930 | 13.911 | 13.944 | 13.953 | 13.988 | 14.022 | 14.056 | 13.986 | 14.019 | |
Rankb | 5 | 9 | 6 | 10 | 2 | 7 | 1 | 4 | 3 | 8 | |
Scenario analysisc | Δ Cost, ¥ ($)a | − 14,581 (− 2111) | 6277 (909) | 9495 (1375) | 31,801 (4604) | 6607 (956) | 26,841 (3885) | − 14,805 (− 2143) | 6542 (947) | 25,963 (3758) | 49,142 (7114) |
Δ QALY | 0.469 | 0.515 | 0.456 | 0.509 | 0.480 | 0.532 | 0.608 | 0.653 | 0.525 | 0.576 | |
ICER, ¥ ($)/QALY | Dominantd | 12,189 (1765) | 20,836 (3016) | 62,473 (9044) | 13,754 (1991) | 50,417 (7298) | Dominantd | 10,018 (1450) | 49,490 (7164) | 85,380 (12,360) |